Multiple sclerosisMassimo Filippi, Maria A. Rocca, Amit Bar‐Or et al.|Nature Reviews Disease Primers|2018Cited by 1.4k
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Jan Lycke, Clas Malmeström et al.|Annals of Neurology|2010Cited by 347
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre studyJens Kühle, A. Martinez, Giulio Disanto et al.|Multiple Sclerosis Journal|2015Cited by 298
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple SclerosisTim Spelman, Jan Lycke, Melinda Magyari et al.|JAMA Neurology|2021Cited by 237
Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromesEster Cantó, Manuel Comabella, Mar Tintoré et al.|Brain|2015Cited by 191